about
Clinical potential of resistin as a novel prognostic biomarker for cellulitisNovel myokine: irisin may be an independent predictor for subclinic atherosclerosis in Behçet's disease.Is the mean platelet volume predictive of hip fractures in the elderly?Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke.Investigation of surfactant protein-D and interleukin-6 levels in patients with blunt chest trauma with multiple rib fractures and pulmonary contusions: a cross-sectional study in Black Sea Region of Turkey.Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats.Mean platelet volume and vitamin D level.Serum levels of homocysteine, asymmetric dimethylarginine and nitric oxide in patients with Parkinson's disease.Clinical significance of neutrophil gelatinase-associated lipocalin in Crimean-Congo hemorrhagic Fever.Is increasing the dose of Entecavir effective in partial virological responders?The evaluation of relationship between adiponectin levels and epicardial adipose tissue thickness with low cardiac risk in Gilbert`s syndrome: an observational study.Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS.Atherogenic index of plasma may be strong predictor of subclinical atherosclerosis in patients with Behçet disease.Biochemical, Histopathological and Immunohistochemical Evaluation of the Protective and Therapeutic Effects of Thymoquinone against Ischemia and Ischemia/Reperfusion Injury in the Rat Ovary.Comment on "The relationship between erectile dysfunction and the atherogenic index of plasma"Comment on "The relationship between atherogenic index of plasma and no‑reflow in patients with acute ST‑segment elevation myocardial infarction who underwent primary percutaneous coronary intervention"Comment: Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial DataComment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19"Comment on "Bilirubin: a novel predictor of hemorrhagic transformation and symptomatic intracranial hemorrhage after mechanical thrombectomy"Comment on "Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies"Comment on "Impact of TNF-Α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the catholic axial spondyloarthritis cohort (CASCO)"Comment on "Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis"Comment on: "High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment"Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesisComment on "usefulness of atherogenic indices and Ca-LDL level to predict subclinical atherosclerosis in patients with psoriatic arthritis?"Comment on "Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?"Comment on 'Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?'Colchicine may not be effective in COVID-19 infection; it may even be harmful?Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)Can COVID-19 cause myalgia with a completely different mechanism? A hypothesisCOVID-19 may affect the endocrine pancreas by activating Na+/H+ exchanger 2 and increasing lactate levelsComment on "ACE inhibitors and COVID-19: We don't know yet"
P50
Q35754330-87A564F5-22AA-4E60-9E15-DA81AC5E50DDQ36762128-763BA937-04C0-40E8-BAB2-85C08E747931Q37129458-A060EB31-4CA6-473F-817C-38B186CED194Q37345463-60FA015D-5036-4586-8C4B-AE2AB4D500C7Q37356227-7E902693-380D-48A7-99C8-6ECBBAA3B226Q37556557-06D008B8-C4EA-4E79-B4B1-78D50EA1A73DQ37628856-5BCF60F4-7844-40DA-971B-BB9F933EF634Q39852913-4B2D58A9-B883-44AE-9632-7D3182B1B8E5Q40169251-48C90C7D-92CA-481A-BB42-30947485805AQ40385406-EC667B02-3502-4774-853A-595C9DB6D661Q44392236-A559AB91-2E40-409F-942C-268956FB96BFQ50051398-D757EA9B-A184-43E6-ACCF-BE8C350AEA90Q50874831-C09ED3F4-54F6-4F57-85D5-29AE71F225B7Q51007610-510CBA36-AA7C-4058-AB96-CBC8975BDDB2Q89455281-FB124624-5580-46B3-A637-F7E9AD774891Q89749599-D34BD59F-600C-41B1-B2FC-E87409497040Q89922560-BD4447A6-FFCA-4C92-BA89-DF9D4AA1D218Q91719793-2C9E2D30-E628-43A7-8735-A9C971363D17Q92507159-CA3F54FA-24CA-465D-874B-2B874ED60E01Q92578487-3E7040E1-3766-49F9-8A10-4092D3959022Q92649310-9642FFFA-D534-4B79-B4FE-E7166D252056Q92751032-FC417558-0396-4FC1-B728-83CF10BE6491Q93063317-EDF705EF-7BB4-4BBA-A047-3BF585CD9EC8Q93230270-A3FB6652-ABD0-4DC0-B900-05AF2D79183CQ94481974-47D284E8-6DBF-46AF-AE25-378775B68578Q94492515-F949C35B-12AE-411F-BE71-BB08E2F9E0BAQ94553673-DCAD1E9B-0351-4545-8713-7AA53F7E23A1Q94564994-EF6516E6-3A29-4397-AC91-C0B4612F4FB2Q94948798-8E841828-CC79-43D0-853D-F532F11F20D8Q95843767-AB40649B-90F7-4D6B-931E-8978649F1D74Q95939274-0CA20E99-54CC-4DFC-8B5A-19762B14BD1BQ96342513-EF4AF653-D781-47AD-99EC-888513EBFBA6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Medine Cumhur Cure
@ast
Medine Cumhur Cure
@en
Medine Cumhur Cure
@es
Medine Cumhur Cure
@nl
type
label
Medine Cumhur Cure
@ast
Medine Cumhur Cure
@en
Medine Cumhur Cure
@es
Medine Cumhur Cure
@nl
prefLabel
Medine Cumhur Cure
@ast
Medine Cumhur Cure
@en
Medine Cumhur Cure
@es
Medine Cumhur Cure
@nl
P106
P31
P496
0000-0001-9253-6459